PL194025B1
(pl)
*
|
1996-10-18 |
2007-04-30 |
Vertex Pharma |
Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
ES2234144T3
(es)
*
|
1997-08-11 |
2005-06-16 |
Boehringer Ingelheim (Canada) Ltd. |
Analogos de peptidos inhibidores de la hepatitis c.
|
GB9806815D0
(en)
*
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
GB9809664D0
(en)
*
|
1998-05-06 |
1998-07-01 |
Hoffmann La Roche |
a-Ketoamide derivatives
|
GB9812523D0
(en)
*
|
1998-06-10 |
1998-08-05 |
Angeletti P Ist Richerche Bio |
Peptide inhibitors of hepatitis c virus ns3 protease
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
AU5788800A
(en)
*
|
1999-07-07 |
2001-01-22 |
Du Pont Pharmaceuticals Company |
Peptide boronic acid inhibitors of hepatitis c virus protease
|
US7122627B2
(en)
|
1999-07-26 |
2006-10-17 |
Bristol-Myers Squibb Company |
Lactam inhibitors of Hepatitis C virus NS3 protease
|
CA2376961A1
(en)
*
|
1999-07-26 |
2001-02-01 |
Bristol-Myers Squibb Pharma Company |
Lactam inhibitors of hepatitis c virus ns3 protease
|
US7026469B2
(en)
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
DE60124080T2
(de)
*
|
2000-03-23 |
2007-03-01 |
Elan Pharmaceuticals, Inc., San Francisco |
Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
|
DE60137207D1
(de)
|
2000-04-05 |
2009-02-12 |
Schering Corp |
Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
|
SK14952002A3
(sk)
|
2000-04-19 |
2003-03-04 |
Schering Corporation |
Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
NZ547204A
(en)
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
BR0112666A
(pt)
|
2000-07-21 |
2003-06-10 |
Schering Corp |
Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
PL206255B1
(pl)
|
2000-07-21 |
2010-07-30 |
Dendreon Corporationdendreon Corporation |
Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
PT1411954E
(pt)
|
2000-10-18 |
2011-03-16 |
Pharmasset Inc |
Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
US6911428B2
(en)
|
2000-12-12 |
2005-06-28 |
Schering Corporation |
Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
|
MY134070A
(en)
|
2001-01-22 |
2007-11-30 |
Isis Pharmaceuticals Inc |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US20030176689A1
(en)
*
|
2001-12-14 |
2003-09-18 |
Michael Joyce |
Inhibitors of hepatitis C virus protease
|
CA2473070C
(en)
|
2002-01-23 |
2009-10-13 |
Schering Corporation |
Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
NZ561851A
(en)
|
2002-04-11 |
2009-05-31 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
EP1506000B9
(en)
|
2002-05-20 |
2011-08-31 |
Bristol-Myers Squibb Company |
Heterocyclicsulfonamide hepatitis c virus inhibitors
|
AU2003299519A1
(en)
|
2002-05-20 |
2004-05-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2004043339A2
(en)
|
2002-05-20 |
2004-05-27 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl p1' hepatitis c virus inhibitors
|
EP2799442A1
(en)
|
2002-06-28 |
2014-11-05 |
IDENIX Pharmaceuticals, Inc. |
Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
AU2011203054B2
(en)
*
|
2003-04-11 |
2012-04-26 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
|
EP2332935A1
(en)
*
|
2003-04-11 |
2011-06-15 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
MXPA05012545A
(es)
|
2003-05-21 |
2006-02-08 |
Boehringer Ingelheim Int |
Compuestos inhibidores de la hepatitis c.
|
ES2586668T3
(es)
|
2003-05-30 |
2016-10-18 |
Gilead Pharmasset Llc |
Análogos de nucleósidos fluorados modificados
|
AU2004258750A1
(en)
|
2003-07-25 |
2005-02-03 |
Centre National De La Recherche Scientifique -Cnrs |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
|
US7576206B2
(en)
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
WO2005021584A2
(en)
|
2003-08-26 |
2005-03-10 |
Schering Corporation |
Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
|
PE20050374A1
(es)
*
|
2003-09-05 |
2005-05-30 |
Vertex Pharma |
Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
|
MXPA06003141A
(es)
*
|
2003-09-22 |
2006-06-05 |
Boehringer Ingelheim Int |
Peptidos macrociclicos activos contra el virus de la hepatitis c.
|
JP4525982B2
(ja)
|
2003-09-26 |
2010-08-18 |
シェーリング コーポレイション |
C型肝炎ウイルスのns3セリンプロテアーゼの大環状インヒビター
|
KR20120010278A
(ko)
|
2003-10-10 |
2012-02-02 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의 억제제
|
PL1680137T3
(pl)
|
2003-10-14 |
2013-04-30 |
F Hoffmann La Roche Ltd |
Makrocykliczny kwas karboksylowy i związek acylosulfonamidowy jako inhibitor replikacji HCV
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
EP1944042A1
(en)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinations for HCV treatment
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1688420A4
(en)
*
|
2003-11-19 |
2008-10-22 |
Japan Tobacco Inc |
5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP2007532479A
(ja)
|
2003-11-20 |
2007-11-15 |
シェーリング コーポレイション |
C型肝炎ウイルスns3プロテアーゼの脱ペプチド化インヒビター
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
ES2358333T3
(es)
*
|
2004-01-21 |
2011-05-09 |
Boehringer Ingelheim International Gmbh |
Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
|
WO2005077969A2
(en)
|
2004-02-04 |
2005-08-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
US20070049593A1
(en)
*
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
ATE428714T1
(de)
|
2004-02-24 |
2009-05-15 |
Japan Tobacco Inc |
Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
KR101316137B1
(ko)
|
2004-02-27 |
2013-10-10 |
머크 샤프 앤드 돔 코포레이션 |
C형 간염 바이러스 ns3 세린 프로테아제의 억제제로서의황 화합물
|
CA2557247A1
(en)
|
2004-02-27 |
2005-09-22 |
Schering Corporation |
Compounds as inhibitors of hepatitis c virus ns3 serine protease
|
KR20060124725A
(ko)
|
2004-02-27 |
2006-12-05 |
쉐링 코포레이션 |
C형 간염 바이러스 ns3 프로테아제의 억제제
|
EP1939213B1
(en)
|
2004-02-27 |
2010-08-25 |
Schering Corporation |
Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
|
WO2005087730A1
(en)
|
2004-02-27 |
2005-09-22 |
Schering Corporation |
3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
|
CN1984922A
(zh)
|
2004-05-20 |
2007-06-20 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
|
WO2005123087A2
(en)
|
2004-06-15 |
2005-12-29 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
US20070265222A1
(en)
|
2004-06-24 |
2007-11-15 |
Maccoss Malcolm |
Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
JP4914355B2
(ja)
|
2004-07-20 |
2012-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎インヒビターペプチド類似体
|
CN101068828A
(zh)
|
2004-08-27 |
2007-11-07 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
|
MX2007003085A
(es)
|
2004-09-14 |
2007-08-02 |
Pharmasset Inc |
Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7468383B2
(en)
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
CA2606195C
(en)
|
2005-05-02 |
2015-03-31 |
Merck And Co., Inc. |
Hcv ns3 protease inhibitors
|
AU2006252553B2
(en)
|
2005-06-02 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Combination of HCV protease inhibitors with a surfactant
|
US20060276404A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
PL1891089T3
(pl)
|
2005-06-02 |
2015-05-29 |
Merck Sharp & Dohme |
Inhibitory proteazy HCV w połączeniu z pokarmem
|
CN101242842A
(zh)
|
2005-06-17 |
2008-08-13 |
诺瓦提斯公司 |
Sanglifehrin在hcv中的用途
|
TWI387603B
(zh)
|
2005-07-20 |
2013-03-01 |
Merck Sharp & Dohme |
Hcv ns3蛋白酶抑制劑
|
EP2305696A3
(en)
|
2005-07-25 |
2011-10-12 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
PE20070210A1
(es)
|
2005-07-29 |
2007-04-16 |
Tibotec Pharm Ltd |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
PL1919904T3
(pl)
|
2005-07-29 |
2014-06-30 |
Janssen R&D Ireland |
Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
|
CN101273028B
(zh)
|
2005-07-29 |
2013-08-21 |
泰博特克药品有限公司 |
丙型肝炎病毒的大环抑制剂
|
MY144895A
(en)
|
2005-07-29 |
2011-11-30 |
Tibotec Pharm Ltd |
Macrocylic inhibitors of hepatitis c virus
|
DK1919898T3
(da)
|
2005-07-29 |
2011-05-02 |
Tibotec Pharm Ltd |
Makrocykliske inhibitorer af hepatitis-C-virus
|
DK1912997T3
(da)
|
2005-07-29 |
2012-01-02 |
Tibotec Pharm Ltd |
Makrocycliske inhibitorer af hepatitis C virus
|
WO2007014924A1
(en)
|
2005-07-29 |
2007-02-08 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis c virus
|
JO2768B1
(en)
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
AU2006275605B2
(en)
|
2005-08-01 |
2011-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic peptides as HCV NS3 protease inhibitors
|
CA2617679A1
(en)
|
2005-08-02 |
2007-02-08 |
Steve Lyons |
Inhibitors of serine proteases
|
JP2009513564A
(ja)
|
2005-08-09 |
2009-04-02 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体
|
NZ566049A
(en)
|
2005-08-19 |
2011-07-29 |
Vertex Pharma |
Processes and intermediates
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
KR20080056295A
(ko)
|
2005-10-11 |
2008-06-20 |
인터뮨, 인크. |
C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
EP2392588A3
(en)
|
2005-11-11 |
2012-03-07 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
AU2007217355B2
(en)
|
2006-02-27 |
2012-06-21 |
Vertex Pharmaceuticals Incorporated |
Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
|
MX2008011868A
(es)
*
|
2006-03-16 |
2008-12-15 |
Vertex Pharma |
Inhibidores deuterados de la proteasa de la hepatitis c.
|
NZ571826A
(en)
|
2006-04-11 |
2012-01-12 |
Novartis Ag |
HCV/HIV inhibitors and their uses
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
US8138164B2
(en)
|
2006-10-24 |
2012-03-20 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
CA2667165A1
(en)
|
2006-10-24 |
2008-05-02 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
AU2007309488B2
(en)
|
2006-10-24 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
WO2008057209A1
(en)
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
WO2008057208A2
(en)
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
CA2673111A1
(en)
|
2006-12-07 |
2008-06-19 |
Schering Corporation |
Ph sensitive matrix formulation
|
US8101595B2
(en)
|
2006-12-20 |
2012-01-24 |
Istituto di Ricerche di Biologia Molecolare P. Angletti SpA |
Antiviral indoles
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
AU2007339382B2
(en)
|
2006-12-22 |
2013-05-02 |
Merck Sharp & Dohme Llc |
4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
|
EP2064181A1
(en)
|
2006-12-22 |
2009-06-03 |
Schering Corporation |
4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
|
MX2009006877A
(es)
|
2006-12-22 |
2009-09-28 |
Schering Corp |
Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
|
EP2118091B1
(en)
|
2007-02-08 |
2015-04-15 |
Janssen Sciences Ireland UC |
Pyrimidine substituted macrocyclic hcv inhibitors
|
US8575208B2
(en)
*
|
2007-02-27 |
2013-11-05 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
ES2379905T3
(es)
*
|
2007-02-27 |
2012-05-04 |
Vertex Pharmceuticals Incorporated |
Co-cristales y composiciones farmacéuticas que los comprenden
|
AU2008219622A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
FR2914920B1
(fr)
|
2007-04-11 |
2011-09-09 |
Clariant Specialty Fine Chem F |
Procede de deacetalisation d'alpha-aminoacetals.
|
ATE548044T1
(de)
|
2007-05-04 |
2012-03-15 |
Vertex Pharma |
Kombinationstherapie zur behandlung von hiv- infektionen
|
FR2916441B1
(fr)
|
2007-05-22 |
2009-08-28 |
Clariant Specialty Fine Chem |
Procede de racemisation d'alpha-aminoacetals optiquement actifs.
|
US8513186B2
(en)
|
2007-06-29 |
2013-08-20 |
Gilead Sciences, Inc. |
Antiviral compounds
|
AR067442A1
(es)
|
2007-06-29 |
2009-10-14 |
Gilead Sciences Inc |
Compuestos antivirales
|
AU2008277440A1
(en)
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis C infections
|
JP5433573B2
(ja)
|
2007-07-19 |
2014-03-05 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ |
抗ウイルス剤としての大環状化合物
|
PE20090995A1
(es)
|
2007-08-29 |
2009-08-03 |
Schering Corp |
Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc)
|
EP2195317B1
(en)
|
2007-08-29 |
2012-01-18 |
Schering Corporation |
2,3-substituted azaindole derivatives for treating viral infections
|
KR20100067652A
(ko)
|
2007-08-29 |
2010-06-21 |
쉐링 코포레이션 |
치환된 인돌 유도체 및 이의 사용방법
|
NZ583699A
(en)
*
|
2007-08-30 |
2012-04-27 |
Vertex Pharma |
Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
EP2222660B1
(en)
|
2007-11-16 |
2014-03-26 |
Merck Sharp & Dohme Corp. |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
US8377928B2
(en)
|
2007-11-16 |
2013-02-19 |
Merck Sharp & Dohme Corp. |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
CN101951769B
(zh)
|
2007-12-21 |
2014-12-31 |
阿维拉制药公司 |
Hcv蛋白酶抑制剂和其用途
|
US8309685B2
(en)
*
|
2007-12-21 |
2012-11-13 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
CN101951770B
(zh)
*
|
2007-12-21 |
2014-12-31 |
阿维拉制药公司 |
Hcv蛋白酶抑制剂和其用途
|
US8293705B2
(en)
|
2007-12-21 |
2012-10-23 |
Avila Therapeutics, Inc. |
HCV protease inhibitors and uses thereof
|
WO2009099596A2
(en)
|
2008-02-04 |
2009-08-13 |
Idenix Pharamaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
FR2927900B1
(fr)
|
2008-02-27 |
2010-09-17 |
Clariant Specialty Fine Chem |
Procede de preparation d'alpha-aminoacetals optiquement actifs.
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
AU2009241445A1
(en)
|
2008-04-28 |
2009-11-05 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
JP5580814B2
(ja)
|
2008-06-13 |
2014-08-27 |
メルク・シャープ・アンド・ドーム・コーポレーション |
3環式インドール誘導体およびその使用方法
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
EP2310095B1
(en)
|
2008-07-22 |
2012-08-29 |
Merck Sharp & Dohme Corp. |
Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
|
AU2009282567B2
(en)
|
2008-08-20 |
2014-10-02 |
Merck Sharp & Dohme Corp. |
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
TW201019939A
(en)
|
2008-08-20 |
2010-06-01 |
Schering Corp |
Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
AU2009282574B2
(en)
|
2008-08-20 |
2014-08-21 |
Merck Sharp & Dohme Corp. |
Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
AU2009282571B2
(en)
|
2008-08-20 |
2014-12-11 |
Merck Sharp & Dohme Corp. |
Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
KR20110098779A
(ko)
|
2008-12-03 |
2011-09-01 |
프레시디오 파마슈티칼스, 인코포레이티드 |
Hcv ns5a의 억제제
|
JP5762971B2
(ja)
|
2008-12-03 |
2015-08-12 |
プレシディオ ファーマシューティカルズ インコーポレイテッド |
Hcvns5aの阻害剤
|
KR20110114582A
(ko)
*
|
2008-12-19 |
2011-10-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hcv ns3 프로테아제 억제제
|
MX2011006891A
(es)
|
2008-12-23 |
2011-10-06 |
Pharmasset Inc |
Fosforamidatos de nucleosidos.
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
EP2376514A2
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Nucleoside analogs
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
EP3021120A1
(en)
|
2009-02-20 |
2016-05-18 |
Michael P. Lisanti |
Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
|
EP2403860B1
(en)
|
2009-03-04 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
|
JP5735482B2
(ja)
|
2009-03-27 |
2015-06-17 |
プレシディオ ファーマシューティカルズ インコーポレイテッド |
縮合環のc型肝炎阻害剤
|
EP2417134B1
(en)
|
2009-04-08 |
2017-05-17 |
Idenix Pharmaceuticals LLC. |
Macrocyclic serine protease inhibitors
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
CA2763140A1
(en)
|
2009-05-29 |
2010-12-02 |
Schering Corporation |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
US8828930B2
(en)
|
2009-07-30 |
2014-09-09 |
Merck Sharp & Dohme Corp. |
Hepatitis C virus NS3 protease inhibitors
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
JP2013512246A
(ja)
|
2009-11-25 |
2013-04-11 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
|
CN102822175A
(zh)
|
2009-12-18 |
2012-12-12 |
埃迪尼克斯医药公司 |
5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
|
CN102725300B
(zh)
|
2009-12-22 |
2015-03-11 |
赛福伦公司 |
蛋白酶体抑制剂及其制备、纯化、和应用的方法
|
CA2785488A1
(en)
|
2009-12-22 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
|
EP2536410B1
(en)
|
2010-02-18 |
2015-09-23 |
Merck Sharp & Dohme Corp. |
Substituted pyrimidine derivatives and their use in treating viral infections
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
MA34147B1
(fr)
|
2010-03-09 |
2013-04-03 |
Merck Sharp & Dohme |
Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
|
AU2011235112B2
(en)
|
2010-03-31 |
2015-07-09 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
MX2012011222A
(es)
|
2010-04-01 |
2013-01-18 |
Centre Nat Rech Scient |
Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
|
EP2575866A4
(en)
|
2010-05-24 |
2013-10-16 |
Presidio Pharmaceuticals Inc |
HCV NS5A INHIBITORS
|
EP2598149A4
(en)
|
2010-07-26 |
2014-09-10 |
Merck Sharp & Dohme |
SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
|
WO2012020036A1
(en)
|
2010-08-13 |
2012-02-16 |
F. Hoffmann-La Roche Ag |
Hepatitis c virus inhibitors
|
JP2013540122A
(ja)
|
2010-09-29 |
2013-10-31 |
メルク・シャープ・エンド・ドーム・コーポレイション |
縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
|
MX2013003945A
(es)
|
2010-10-08 |
2013-06-05 |
Novartis Ag |
Formulaciones de vitamina e como inhibidoras de sulfamida ns3.
|
AU2011336632B2
(en)
|
2010-11-30 |
2015-09-03 |
Gilead Pharmasset Llc |
Compounds
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
WO2012107584A1
(en)
|
2011-02-11 |
2012-08-16 |
Universite Pierre Et Marie Curie (Paris 6) |
Methods for predicting outcome of a hepatitis virus infection
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012123298A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2012175700A1
(en)
|
2011-06-23 |
2012-12-27 |
Digna Biotech, S. L. |
Treatment of chronic hepatitis c with ifn-a5 combined with ifn-a2b in a cohort of patients
|
WO2012175581A1
(en)
|
2011-06-24 |
2012-12-27 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
CA2843495A1
(en)
|
2011-08-03 |
2013-02-07 |
Cytheris |
Hcv immunotherapy
|
PL2742356T3
(pl)
|
2011-08-11 |
2016-11-30 |
|
Środki prognostyczne w leczeniu nowotworów
|
WO2013033899A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033901A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013033900A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
|
WO2013039855A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013039920A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2755981A4
(en)
|
2011-09-14 |
2015-03-25 |
Merck Sharp & Dohme |
HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
|
CN103917541B
(zh)
|
2011-10-10 |
2016-08-17 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒化合物
|
TW201331221A
(zh)
|
2011-10-14 |
2013-08-01 |
Idenix Pharmaceuticals Inc |
嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
|
US9328138B2
(en)
|
2011-11-15 |
2016-05-03 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
CN104185420B
(zh)
|
2011-11-30 |
2017-06-09 |
埃默里大学 |
用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
|
CA2855574A1
(en)
|
2011-12-16 |
2013-06-20 |
F. Hoffmann-La Roche Ag |
Inhibitors of hcv ns5a
|
MX350809B
(es)
|
2011-12-20 |
2017-09-20 |
Riboscience Llc |
Derivados nucleósidos con sustitución 2',4'-difluoro-2'-metilo como inhibidores de la replicación del arn del vhc.
|
KR101687084B1
(ko)
|
2011-12-20 |
2016-12-15 |
리보사이언스 엘엘씨 |
Hcv rna 복제의 억제제로서 4'-아지도, 3'-플루오로 치환된 뉴클레오시드 유도체
|
US20140356325A1
(en)
|
2012-01-12 |
2014-12-04 |
Ligand Pharmaceuticals Incorporated |
Novel 2'-c-methyl nucleoside derivative compounds
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
US9234048B2
(en)
|
2012-01-18 |
2016-01-12 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
WO2013112881A1
(en)
|
2012-01-27 |
2013-08-01 |
Thomas Jefferson University |
Mct protein inhibitor-related prognostic and therapeutic methods
|
US20130217644A1
(en)
|
2012-02-13 |
2013-08-22 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
|
EA201491511A1
(ru)
|
2012-02-16 |
2014-12-30 |
АрКьюИкс ФАРМАСЬЮТИКАЛС, ИНК. |
Линейные пептидные антибиотики
|
US9090559B2
(en)
|
2012-02-24 |
2015-07-28 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
AU2013266393B2
(en)
|
2012-05-22 |
2017-09-28 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
US20140010783A1
(en)
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
GEP201706723B
(en)
|
2012-10-08 |
2017-08-25 |
Idenix Pharmaceuticals Llk |
2'-chloro nucleoside analogs for hcv infection
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
CA2892589A1
(en)
|
2013-01-23 |
2014-07-31 |
F. Hoffmann-La Roche Ag |
Antiviral triazole derivatives
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
CN105008350B
(zh)
|
2013-03-05 |
2018-05-08 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒化合物
|
BR112015023761A2
(pt)
*
|
2013-03-15 |
2017-07-18 |
Adaerata Lp |
moduladores de molécula pequena de pcsk9 e seus métodos e usos
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
EP2986290A4
(en)
|
2013-04-19 |
2017-01-04 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
AU2014265293B2
(en)
|
2013-05-16 |
2019-07-18 |
Riboscience Llc |
4'-Fluoro-2'-methyl substituted nucleoside derivatives
|
US9249176B2
(en)
|
2013-05-16 |
2016-02-02 |
Riboscience Llc |
4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
NZ716840A
(en)
|
2013-08-27 |
2017-06-30 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
US10167298B2
(en)
|
2013-10-30 |
2019-01-01 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
US10449210B2
(en)
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
WO2015134561A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
EP3114122A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
CN106687118A
(zh)
|
2014-07-02 |
2017-05-17 |
配体药物公司 |
前药化合物及其用途
|
CN116731101A
(zh)
|
2016-06-01 |
2023-09-12 |
雅斯娜 |
用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物
|
CN109476637B
(zh)
|
2016-06-21 |
2022-02-01 |
奥瑞恩眼科有限责任公司 |
杂环脯氨酰胺衍生物
|
US10526315B2
(en)
|
2016-06-21 |
2020-01-07 |
Orion Ophthalmology LLC |
Carbocyclic prolinamide derivatives
|
CN111194217B
(zh)
|
2017-09-21 |
2024-01-12 |
里伯赛恩斯有限责任公司 |
作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
|
AU2019207625A1
(en)
|
2018-01-09 |
2020-07-30 |
Ligand Pharmaceuticals, Inc. |
Acetal compounds and therapeutic uses thereof
|